CODX

Co-Diagnostics Inc. (CODX) | Rumor.io

Co-Diagnostics

CODX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,764

Bullish sentiment (50-day avg)51%

Price to earnings ratio-0.03

Market capitalization7.7M

Earnings per share-25.9

Dividend yield (TTM)—

Revenue (annual)622.5K

Net income (annual)-46.9M

Social

What share of all stock conversation is about CODX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0.01% +0

Sep 16

Co-Diagnostics, Inc. ($CODX) announced a collaboration with ReadyGo Diagnostics Ltd. to evaluate blood-based molecular testing at the point of need, starting with Ebola.
The partnership aims to leverage Co-Diagnostics' PCR technology and ReadyGo's ability to extract DNA from a blood sample, which could potentially revolutionize blood-based DNA testing.
The collaboration may have significant implications for the company's future, with some experts speculating about the potential for a major grant or acquisition, while others are skeptical about the effectiveness of blood-based DNA testing.

Generated by AI

Sentiment

Of the messages about CODX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% -25	25% -34.54	73.91% +3.8
Bearish	—	100% +25	75% +34.54	26.09% -3.8

Bullish· Jul 1

$CODX has a low float, which can lead to rapid price movements when the market "wakes up".
The stock has reclaimed its 200-day moving average, indicating that buyers are stepping back in.
$CODX is heavily shorted, with a high short interest percentage, and is poised for a significant price increase following news pending.

Bearish· Jul 1

The stock is heavily shorted and has a high short interest percentage, which could lead to a short squeeze.
The company's recent news, such as completing clinical studies for a flu test, may not be enough to drive the stock price higher, especially if it's accompanied by dilution.
The stock's price action, including its halt in downside movement, may be due to market manipulation, with only a few market makers and dark pools involved in the trading.

Generated by AI

Topics

Of the messages about CODX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	75%	1.64%
Controversies	0%	0%	10%	0.02%
Technical Analysis	0%	0%	15%	24.28%
Macro	0%	0%	0%	47.25%
Analysts	0%	0%	0%	26.77%
Earnings	0%	0%	0%	0.03%

Earnings· Nov 11

Co-Diagnostics, Inc. (CODX) reported Q3 diluted earnings of $0.38 per share, beating analysts' expectations of $0.21.
The company's revenue rose to $30.1 million, exceeding analysts' estimates of $24.3 million.
For full-year fiscal 2021, Co-Diagnostics projected diluted EPS of $1.07 to $1.16 on revenue of $96 million to $100 million, above analysts' estimates of $0.98 and $95.2 million.

Analysts· May 20

Co-Diagnostics, Inc. (CODX) has been upgraded to "buy" by Maxim Group, with a price target of $30.
H.C. Wainwright analyst Raghuram Selvaraju has raised the price target on Co-Diagnostics (CODX) to $35, citing the company's tremendous growth in revenue for Q1.
Analysts seem to be mildly confident about CODX, with a buy consensus of 80% among 2 analysts.

Announcements· May 26

Co-Diagnostics, Inc. (CODX) has advanced its PCR assay development strategy for the Bundibugyo virus, currently causing an Ebola outbreak in the Democratic Republic of the Congo and Uganda, with the support of its Indian joint venture CoSara.
The joint assay development strategy aims to more rapidly address the needs of the international community if the outbreak expands globally or requires localized support in the affected areas.
Co-Diagnostics has a unique, patented platform for molecular diagnostic tests, and its Co-Dx PCR platform is gaining traction as molecular diagnostics names heat up, with recent focus on its point-of-care platform and liquid biopsy and nucleic acid detection markets.

Controversies· Sep 9

Co-Diagnostics, Inc. (CODX) is facing a securities class action lawsuit.
The lawsuit involves allegations against Co-Diagnostics' shareholders.
The company has experienced a significant loss, with its stock price declining by over 30%.

Technical Analysis· May 28

The author notes that $CODX needs a 5-minute close above $10.90 for potential entries.
A potential move to $11.71 and then $13.36 is seen if $9.23 holds as support.
The stock has formed a parabolic breakout after hitting a recent low, indicating strong speculative momentum with resistance at $13.54 and support at $8.12.

Generated by AI

Community

Of the messages about CODX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	92.86%	70.99%	17.37%
Newcomers	0%	7.14%	29.01%	82.63%

Regulars· Sep 16

The collaboration between Co-Diagnostics, Inc. ($CODX) and ReadyGo Diagnostics Ltd. is focused on evaluating blood-based molecular testing at the point of need, starting with Ebola.
The partnership between the two companies may be hindered by the challenges of extracting and analyzing DNA from blood samples, as neither company has the technology to clean up the sample well enough for PCR to work effectively.
Co-Diagnostics, Inc. ($CODX) is running out of cash and may need to consider a reverse split or acquisition by a larger company to stay afloat, and the FDA approval of their ABR multiplex test by Christmas time could be a significant milestone in the company's development.

Newcomers· Aug 19

Newcomers are focused on the potential of Co-Diagnostics as a "beautiful opportunity" with a price of $1.32, comparing it to the struggling $MRNA stock.
Some newcomers believe Co-Diagnostics is undervalued and have identified it as a "cancer play" getting volume, with a price of $1.30 and a strong base building.
Others are predicting a breakout for Co-Diagnostics, citing positive cancer news and strong volume, with a price above the volume-weighted average price (VWAP) and analyst targets of $4++.

Generated by AI

News

Co-Diagnostics annual meeting adjourned again due to lack of quorum

4d agoInvesting.com

Co-Diagnostics to Participate in Global Health Events During UN General Assembly Week

6d agoMorningstar

Co-Diagnostics to Participate in Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 2026

12d agoYahoo Finance

Co-Diagnostics, Inc. (CODX) Shareholder/Analyst Call - Slideshow (NASDAQ:CODX) 2026-09-16

13d agoSeeking Alpha

Co-Diagnostics partners with ReadyGo on blood-based testing

13d agoInvesting.com

Co-Diagnostics enters agreement with ReadyGo Diagnostics for technology evaluation

14d agoInvesting.com

Also Discussed

Investors talking about CODX also mention

#	Name	Attention
1	Nanoviricides Inc.NNVC	0%0
2	Aytu BioPharma, Inc.AYTU	0%0
3	iBio, Inc.IBIO	0%0
4	Inovio Pharmaceuticals Inc.INO	0%+0
5	VXRT - Vaxart, Inc.	——
6	BIMI - BIMI International Medical Inc.	——
7	Sorrento Therapeutics Inc.SRNE	0%0
8	China Pharma Holdings, Inc.CPHI	0%new
9	Genprex Inc. Common StockGNPX	0%0
10	Biomerica Inc.BMRA	0%0

Co-Diagnostics Inc.

Healthcare
Medical Devices

Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and markets nucleic acid-based testing technologies for infectious disease detection and related applications. Co-Diagnostics focuses on PCR-based solutions, including the Co-Dx PCR platform for point-of-care and at-home testing, as well as diagnostic tests for conditions such as COVID-19, influenza, tuberculosis, hepatitis, malaria, dengue, and other pathogens. The company also develops molecular tools for mosquito testing, agricultural pathogen detection, and genetic analysis in plant and animal genomes. Its proprietary Co-Primers technology is designed to support highly specific test development and simplify complex molecular testing workflows. Headquartered in Salt Lake City, Utah, Co-Diagnostics serves healthcare, public health, research, and agricultural markets through its diagnostics products and development platforms.

Website

Location

2401 S. Foothill Drive

Salt Lake City, UT, 84109

United States

Social

What share of all stock conversation is about CODX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0.01% +0

Sep 16

Co-Diagnostics, Inc. ($CODX) announced a collaboration with ReadyGo Diagnostics Ltd. to evaluate blood-based molecular testing at the point of need, starting with Ebola.
The partnership aims to leverage Co-Diagnostics' PCR technology and ReadyGo's ability to extract DNA from a blood sample, which could potentially revolutionize blood-based DNA testing.
The collaboration may have significant implications for the company's future, with some experts speculating about the potential for a major grant or acquisition, while others are skeptical about the effectiveness of blood-based DNA testing.

Generated by AI

Sentiment

Of the messages about CODX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% -25	25% -34.54	73.91% +3.8
Bearish	—	100% +25	75% +34.54	26.09% -3.8

Bullish· Jul 1

$CODX has a low float, which can lead to rapid price movements when the market "wakes up".
The stock has reclaimed its 200-day moving average, indicating that buyers are stepping back in.
$CODX is heavily shorted, with a high short interest percentage, and is poised for a significant price increase following news pending.

Bearish· Jul 1

The stock is heavily shorted and has a high short interest percentage, which could lead to a short squeeze.
The company's recent news, such as completing clinical studies for a flu test, may not be enough to drive the stock price higher, especially if it's accompanied by dilution.
The stock's price action, including its halt in downside movement, may be due to market manipulation, with only a few market makers and dark pools involved in the trading.

Generated by AI

Topics

Of the messages about CODX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	75%	1.64%
Controversies	0%	0%	10%	0.02%
Technical Analysis	0%	0%	15%	24.28%
Macro	0%	0%	0%	47.25%
Analysts	0%	0%	0%	26.77%
Earnings	0%	0%	0%	0.03%

Earnings· Nov 11

Co-Diagnostics, Inc. (CODX) reported Q3 diluted earnings of $0.38 per share, beating analysts' expectations of $0.21.
The company's revenue rose to $30.1 million, exceeding analysts' estimates of $24.3 million.
For full-year fiscal 2021, Co-Diagnostics projected diluted EPS of $1.07 to $1.16 on revenue of $96 million to $100 million, above analysts' estimates of $0.98 and $95.2 million.

Analysts· May 20

Co-Diagnostics, Inc. (CODX) has been upgraded to "buy" by Maxim Group, with a price target of $30.
H.C. Wainwright analyst Raghuram Selvaraju has raised the price target on Co-Diagnostics (CODX) to $35, citing the company's tremendous growth in revenue for Q1.
Analysts seem to be mildly confident about CODX, with a buy consensus of 80% among 2 analysts.

Announcements· May 26

Co-Diagnostics, Inc. (CODX) has advanced its PCR assay development strategy for the Bundibugyo virus, currently causing an Ebola outbreak in the Democratic Republic of the Congo and Uganda, with the support of its Indian joint venture CoSara.
The joint assay development strategy aims to more rapidly address the needs of the international community if the outbreak expands globally or requires localized support in the affected areas.
Co-Diagnostics has a unique, patented platform for molecular diagnostic tests, and its Co-Dx PCR platform is gaining traction as molecular diagnostics names heat up, with recent focus on its point-of-care platform and liquid biopsy and nucleic acid detection markets.

Controversies· Sep 9

Co-Diagnostics, Inc. (CODX) is facing a securities class action lawsuit.
The lawsuit involves allegations against Co-Diagnostics' shareholders.
The company has experienced a significant loss, with its stock price declining by over 30%.

Technical Analysis· May 28

The author notes that $CODX needs a 5-minute close above $10.90 for potential entries.
A potential move to $11.71 and then $13.36 is seen if $9.23 holds as support.
The stock has formed a parabolic breakout after hitting a recent low, indicating strong speculative momentum with resistance at $13.54 and support at $8.12.

Generated by AI

Community

Of the messages about CODX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	92.86%	70.99%	17.37%
Newcomers	0%	7.14%	29.01%	82.63%

Regulars· Sep 16

The collaboration between Co-Diagnostics, Inc. ($CODX) and ReadyGo Diagnostics Ltd. is focused on evaluating blood-based molecular testing at the point of need, starting with Ebola.
The partnership between the two companies may be hindered by the challenges of extracting and analyzing DNA from blood samples, as neither company has the technology to clean up the sample well enough for PCR to work effectively.
Co-Diagnostics, Inc. ($CODX) is running out of cash and may need to consider a reverse split or acquisition by a larger company to stay afloat, and the FDA approval of their ABR multiplex test by Christmas time could be a significant milestone in the company's development.

Newcomers· Aug 19

Newcomers are focused on the potential of Co-Diagnostics as a "beautiful opportunity" with a price of $1.32, comparing it to the struggling $MRNA stock.
Some newcomers believe Co-Diagnostics is undervalued and have identified it as a "cancer play" getting volume, with a price of $1.30 and a strong base building.
Others are predicting a breakout for Co-Diagnostics, citing positive cancer news and strong volume, with a price above the volume-weighted average price (VWAP) and analyst targets of $4++.

Generated by AI

Co-Diagnostics

Social

Sep 16

Bullish· Jul 1

Bearish· Jul 1

Earnings· Nov 11

Analysts· May 20

Announcements· May 26

Controversies· Sep 9

Technical Analysis· May 28

Regulars· Sep 16

Newcomers· Aug 19

Co-Diagnostics annual meeting adjourned again due to lack of quorum

Co-Diagnostics to Participate in Global Health Events During UN General Assembly Week

Co-Diagnostics to Participate in Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 2026

Co-Diagnostics, Inc. (CODX) Shareholder/Analyst Call - Slideshow (NASDAQ:CODX) 2026-09-16

Co-Diagnostics partners with ReadyGo on blood-based testing

Co-Diagnostics enters agreement with ReadyGo Diagnostics for technology evaluation

Also Discussed

Co-Diagnostics Inc.

Company Information

Location

Co-Diagnostics annual meeting adjourned again due to lack of quorum

Co-Diagnostics to Participate in Global Health Events During UN General Assembly Week

Co-Diagnostics to Participate in Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 2026

Co-Diagnostics, Inc. (CODX) Shareholder/Analyst Call - Slideshow (NASDAQ:CODX) 2026-09-16

Co-Diagnostics partners with ReadyGo on blood-based testing

Co-Diagnostics enters agreement with ReadyGo Diagnostics for technology evaluation

Also Discussed

Social

Sep 16

Bullish· Jul 1

Bearish· Jul 1

Earnings· Nov 11

Analysts· May 20

Announcements· May 26

Controversies· Sep 9

Technical Analysis· May 28

Regulars· Sep 16

Newcomers· Aug 19